Compare CADL & OXLC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CADL | OXLC |
|---|---|---|
| Founded | 1999 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 455.8M | 498.0M |
| IPO Year | 2021 | 2010 |
| Metric | CADL | OXLC |
|---|---|---|
| Price | $4.99 | $4.96 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 10 | 1 |
| Target Price | ★ $17.67 | $6.00 |
| AVG Volume (30 Days) | 1.4M | ★ 2.3M |
| Earning Date | 11-12-2026 | 11-01-2023 |
| Dividend Yield | N/A | ★ 18.86% |
| EPS Growth | ★ 58.62 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $125,000.00 | N/A |
| Revenue This Year | N/A | $136.15 |
| Revenue Next Year | N/A | $5.51 |
| P/E Ratio | ★ N/A | $7.72 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.35 | $4.62 |
| 52 Week High | $14.00 | $15.39 |
| Indicator | CADL | OXLC |
|---|---|---|
| Relative Strength Index (RSI) | 25.65 | 20.02 |
| Support Level | $4.62 | $4.62 |
| Resistance Level | $5.51 | $10.10 |
| Average True Range (ATR) | 0.70 | 0.26 |
| MACD | -0.33 | 0.04 |
| Stochastic Oscillator | 1.62 | 15.65 |
Candel Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing off-the-shelf viral immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. The immune cells induced by these viral immunotherapies are believed to target patients' specific tumor antigens, potentially improving responses in immunologically hot tumors while at the same time infiltrating the tumor microenvironment, transforming non-inflamed cold tumors with limited immune response into hot tumors. The company has established two clinical off-the-shelf viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.
Oxford Lane Capital Corp is a non-diversified closed-end management investment company. The fund's investment objective is to maximize portfolio's risk adjusted total return, and currently seek to achieve investment objective by investing in structured finance investments, specifically the equity and junior debt tranches of CLO vehicles, which are collateralized by a diverse portfolio of senior secured loans made to companies whose debt is unrated or is rated below investment grade (the Senior Loans) and, to a limited. Its investment plan also includes investing in warehouse facilities, which are financing structures intended to aggregate senior loans that may be used to form the basis of a CLO vehicle.